Coosemans, A; Vankerckhoven, A; Baert, T; Boon, L; Ruts, H; Riva, M; Blagden, S; ... Vergote, I; + view all Coosemans, A; Vankerckhoven, A; Baert, T; Boon, L; Ruts, H; Riva, M; Blagden, S; Delforge, M; Concin, N; Mirza, MR; Ledermann, JA; du Bois, A; Vergote, I; - view fewer (2019) Combining conventional therapy with immunotherapy: A risky business? European Journal of Cancer , 113 pp. 41-44. 10.1016/j.ejca.2019.02.014.

Preview	Text (Article) Ledermann_Combining conventional therapy with immunotherapy. A risky business_AAM2.pdf - Accepted Version Download (683kB) | Preview
	Slideshow (Supplementary Material) Ledermann_Combining conventional therapy with immunotherapy. A risky business_Supp1.pptx - Accepted Version Download (89kB)

Abstract

Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as CSVJSONXML

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item